semaglutide and ovarian cancer Everyone is talking about Ozempic Wegovy for weight loss. But as a gynecologic oncologist what has my attention is what these medications may be doing to risk. Here is what Could GLP-1 Weight Loss Drugs

Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, as well as tirzepatide, which is the active ingredient in Eli Lily's Mounjaro and Zepbound, are considered GLP-1 drugs

Additional risk factors include: Previous significant weight fluctuations or yo-yo dieting Genetic factors affecting skin quality and collagen production Smoking history, which impairs skin elasticity Inadequate protein intake during weight loss, leading to muscle loss Insufficient resistance exercise to maintain muscle mass Dehydration or poor nutritional status Patients with multiple risk factors should discuss realistic expectations with their GP or diabetes specialist nurse before commencing semaglutide therapy

Price: A single 3 mL pen will cost a maximum of $11, and a five-pack will be no more than $55

These also claim to support visceral fat reduction and activate metabolism